A Metabolically Stable Apelin-13 Analog Acting as a Potent ITo Potassium Current Blocker with Potential Benefits for Brugada Syndrome
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26062735 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Juan Antonio Contreras Vite und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology of Sherbrooke, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada. Hauptthemen laut MEDLINE: Brugada Syndrome, Potassium Channel Blockers, Intercellular Signaling Peptides and Proteins. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Heart and Stroke Foundation, Canadian Institutes for Health Research.
Abstract (Originalsprache)
Apelin serves as the endogenous ligand for the APJ receptor and enhances cardiac contractility without significantly affecting potassium currents. However, its short in vivo half-life limits clinical application, prompting the development of metabolically stable APJ receptor agonists. This study employed the patch-clamp technique to investigate the effects of the C-terminally modified apelin-13-2Nal derivative (2Nal) on action potential dynamics, rapid sodium (INa), and transient potassium (ITO) currents in rat cardiomyocytes. We discovered that 2Nal prolongs ventricular action potential duration by selectively blocking ITo. Dose-response analysis indicated that 2Nal acts as a partial antagonist of ITO, achieving a maximum blockade of 47%, with an apparent EC50 of 0.3 nM, while not affecting INa. Our lab previously found that an imbalance between ITo and INa currents contributes to the development of cardiac arrhythmias in conditions like Brugada syndrome. Currently, few therapeutic options exist to safely address this imbalance, as sodium channel openers cannot restore it, and most ITo blockers are cardiotoxic. The selective blockade of ITo by 2Nal that we describe here helps restore the balance of electrical currents between ITo and INa. Our study presents a novel, safe partial antagonist of ITo that may help prevent arrhythmias associated with Brugada syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacology of Sherbrooke, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
ORCID-Profile: Léa Théroux, Mannix Auger-Messier, Pierre-Luc Boudreault, Philippe Sarret, Olivier Lesur, Robert Dumaine
Förderung
- CIHR
- Canadian Heart and Stroke Foundation
- Canadian Institutes for Health Research
Zitieren
APA
Contreras Vite, J. A., Tiffinger, A., Théroux, L., Morin, N., Auger-Messier, M., Boudreault, P. L., Sarret, P., Lesur, O., & Dumaine, R. (2025). A Metabolically Stable Apelin-13 Analog Acting as a Potent ITo Potassium Current Blocker with Potential Benefits for Brugada Syndrome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062735
Vancouver
Contreras Vite JA, Tiffinger A, Théroux L, Morin N, Auger-Messier M, Boudreault PL, et al. A Metabolically Stable Apelin-13 Analog Acting as a Potent ITo Potassium Current Blocker with Potential Benefits for Brugada Syndrome. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062735
BibTeX
@article{ContrerasVite2025,
author = {Contreras Vite, Juan Antonio and Tiffinger, Alexandria and Théroux, Léa and Morin, Nathalie and Auger-Messier, Mannix and Boudreault, Pierre-Luc and Sarret, Philippe and Lesur, Olivier and Dumaine, Robert},
title = {A Metabolically Stable Apelin-13 Analog Acting as a Potent ITo Potassium Current Blocker with Potential Benefits for Brugada Syndrome},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26062735}
}
EUVIMED